Web Exclusives

In shared decision-making, patients communicate their preferences and values to their healthcare team when treatment decisions are made. Patients who take an active role in the process tend to be more satisfied with their quality of care.
Oral medications are being used increasingly in cancer treatment plans and are more convenient to take compared with medications administered in the doctor’s office or hospital. Oral treatments, however, have their own set of challenges that require effective communication between the patient and the healthcare team.
CAR T-Cell Therapy Emerging for Chronic Lymphocytic Leukemia
Chimeric antigen receptor (CAR) T-cell therapy could soon expand into chronic lymphocytic leukemia (CLL). Early clinical trials have shown responses in patients with CLL refractory to other therapies. Predicting which patients will respond is key to advancing CAR T-cell therapy into CLL.
Targeted Therapy Dominates CLL Treatment Landscape
Targeted therapy is at the forefront of chronic lymphocytic leukemia (CLL) treatment. In many cases, targeted agents offer superior outcomes to chemotherapy, with more manageable side effects. Multiple targeted therapy options are available, and some choices depend on certain molecular markers.
Cytogenetic Testing in Chronic Lymphocytic Leukemia
Cytogenetic testing is used to identify genomic aberrations in patients with chronic lymphocytic leukemia (CLL). It estimates a patient’s outcomes and can predict response to certain therapies, and therefore is recommended for all patients with CLL at diagnosis.
Acalabrutinib Alone or in Combination More Effective than Chemoimmunotherapy in Previously Untreated CLL
A new study presented at a major medical meeting showed that fewer patients with treatment-naïve chronic lymphocytic leukemia (CLL) who were treated with acalabrutinib alone or in combination with obinutuzumab had disease progression or died compared with a group of patients treated with the combination of obinutuzumab and chemotherapy.
Triplet Regimen with Acalabrutinib Is Highly Active in Untreated Chronic Lymphocytic Leukemia
A 3-drug regimen of acalabrutinib, venetoclax, and obinutuzumab was highly effective in removing all traces of disease from the bone marrow of patients with chronic lymphocytic leukemia, according to study results presented at the American Society of Hematology annual meeting.
Ovarian Cancer Patient Advocacy Organizations
Ovarian Cancer
There are a number of excellent organizations providing resources and support to you as a patient with ovarian cancer or a caregiver.
Understanding Pancreatic Cancer
Pancreatic Cancer
Pancreatic cancer is difficult to diagnose early, because it often has no symptoms until much later, and it often goes undiagnosed until the cancer is advanced or metastatic, when it can no longer be cured.
Pancreatic Cancer Treatment Explained
Pancreatic CancerRadiation Therapy
Depending on the cancer type and stage, along with individual patient factors, pancreatic cancer can be treated with surgery, radiation, chemotherapy, immunotherapy, targeted therapy, supportive care, or a combination of these treatments.
Page 5 of 15
Results 41 - 50 of 143

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.